Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 815-824

  Hadji, Peyman ^a   Aapro, Matti ^b   Costa, Luis ^c   Gnant, Michael ^d  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b CLINIQUE DE GENOLIER   (Switzerland)

^c HOSPITAL DE SANTA MARIA   (Portugal)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antiresorptive therapy; Bisphosphonates; Bone metastases; Safety; Skeletal related events

Indexed keywords

ALENDRONIC ACID; ANTIBIOTIC AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CISPLATIN; CLODRONIC ACID; DENOSUMAB; IBANDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTHRALGIA; BONE DENSITY; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CEREBROVASCULAR ACCIDENT; CHILL; COLORECTAL CANCER; CONJUNCTIVITIS; CRANIAL NERVE PARALYSIS; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EPISCLERITIS; ESOPHAGITIS; ESOPHAGUS CANCER; EYE DISEASE; EYELID EDEMA; FEVER; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART ARREST; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INFECTION; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; LUNG NON SMALL CELL CANCER; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MOUTH CANCER; MOUTH LESION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; ORBIT INFLAMMATION; OSTEOLYSIS; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SCLERITIS; SIDE EFFECT; SKELETAL RELATED EVENT; SOLID TUMOR; STOMACH CANCER; UNITED KINGDOM; UNITED STATES; VOMITING;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; FEMALE; FRACTURES, BONE; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84861670957     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.03.002     Document Type: Review

References (149)

1. American Cancer Society Cancer Facts & Figures 2010 2010, American Cancer Society, Atlanta, GA.
2. Aapro M., Abrahamsson P.A., Body J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19:420-432.
3. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 2009, 69:73-82.
4. Van Poznak C.H., Temin S., Yee G.C., et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011, 29:1221-1227.
5. Body J.J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003, 14:1399-1405.
6. Body J.J., Diel I.J., Lichinitzer M., et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004, 90:1133-1137.
7. Conte P.F., Latreille J., Mauriac L., et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J Clin Oncol 1996, 14:2552-2559.
8. Hultborn R., Gundersen S., Ryden S., et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 1999, 19:3383-3392.
9. Kanis J.A., McCloskey E.V., Powles T., Paterson A.H., Ashley S., Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999, 79:1179-1181.
10. Kohno N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005, 23:3314-3321.
11. Kristensen B., Ejlertsen B., Groenvold M., Hein S., Loft H., Mouridsen H.T. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999, 246:67-74.
12. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001, 7:377-387.
13. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98:1735-1744.
14. Rosen L.S., Gordon D., Tchekmedyian N.S., et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004, 100:2613-2621.
15. Rosen L.S., Gordon D., Tchekmedyian S., et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003, 21:3150-3157.
16. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002, 94:1458-1468.
17. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96:879-882.
18. Tripathy D., Lichinitzer M., Lazarev A., et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol 2004, 15:743-750.
19. Hadji P., Ziller M., Maskow C., Albert U., Kalder M. The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. Eur J Cancer 2009, 45:3205-3212.
20. Hadji P. Menopausal symptoms and adjuvant therapy-associated adverse events. Endocr Relat Cancer 2008, 15:73-90.
21. Hadji P., Bundred N. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer. Semin Oncol 2007, 34:S4-S10.
22. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593.
23. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
24. Roato I., D'Amelio P., Gorassini E., et al. Osteoclasts are active in bone forming metastases of prostate cancer patients. PLoS One 2008, 3:e3627.
25. Demers L.M., Costa L., Lipton A. Biochemical markers and skeletal metastases. Cancer 2000, 88:2919-2926.
26. Gnant M., Hadji P. Prevention of bone metastases and management of bone health in early breast cancer. Breast Cancer Res 2010, 12:216.
27. Hadji P., Gnant M., Aapro M., Lipton A., Coleman R. Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Crit Rev Oncol Hematol 2011, 79:175-188.
28. Rothstein A. Denosumab safety FDA analysis. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM179782.pdf.
29. Major P.P. Preserving functional independence in elderly patients with cancer-associated bone disease: the role of zoledronic acid. Aging Health 2009, 5:151-164.
30. Zometa® (zoledronic acid) injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
31. Xgeva® prescribing information. Thousand Oaks, CA: Amgen Inc.; 2010.
32. Paterson A.H., Powles T.J., Kanis J.A., McCloskey E., Hanson J., Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11:59-65.
33. Kanis J.A., Powles T., Paterson A.H., McCloskey E.V., Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone 1996, 19:663-667.
34. Lipton A., Theriault R.L., Hortobagyi G.N., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88:1082-1090.
35. Stopeck A.T., Lipton A., Body J.J., et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28:5132-5139.
36. Henry D.H., Costa L., Goldwasser F., et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29:1125-1132.
37. Fizazi K., Carducci M., Smith M., et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
38. Pavlakis N, Schmidt RL, Stockler M. Bisphosphonates for breast cancer (review). Cochrane Database Syst Rev 2005;CD003474.
39. Bonefos® (disodium clodronate) [package insert]. Oy, Turku, Finland: Bayer Shering Pharma; 2008.
40. Boniva® (ibandronate sodium) injection [package insert]. Nutley, NJ: Roche Therapeutics, Inc.; 2006.
41. Bondronat® Swiss Summary of Product Characteristics. Roche Diagnostics GmbH and Roche Products Limited.
42. Aredia® (pamidronate) injection [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2008.
43. Hines S.L., Mincey B., Dentchev T., et al. Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC. Breast Cancer Res Treat 2009, 117:603-609.
44. Brufsky A.M., Bosserman L.D., Caradonna R.R., et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77-85.
45. Eidtmann H., de Boer R., Bundred N., et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol 2010, 21:2188-2194.
46. Llombart A, Frassoldati A, Paija O, et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up [poster]. Presented at: American Society of Clinical Oncology 2009 Breast Cancer Symposium, October 8-10, 2009, San Francisco, CA. [Abstract 213].
47. Saarto T., Vehmanen L., Elomaa I., Valimaki M., Makela P., Blomqvist C. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer. Br J Cancer 2001, 84:1047-1051.
48. Confavreux C.B., Fontana A., Guastalla J.P., Munoz F., Brun J., Delmas P.D. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007, 41:346-352.
49. Greenspan S.L., Brufsky A., Lembersky B.C., et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008, 26:2644-2652.
50. Van Poznak C., Hannon R.A., Mackey J.R., et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010, 28:967-975.
51. Singh S., Cuzick J., Edwards R., et al. Effect of anastrozole on bone mineral density after one year of treatment: results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II) [abstract]. Breast Cancer Res Treat 2007, 106:S9. [Abstract 28].
52. Lester J.E., Dodwell D., Purohit O.P., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14:6336-6342.
53. Ellis G.K., Bone H.G., Chlebowski R., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008, 26:4875-4882.
54. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840-849.
55. Gnant M.F., Mlineritsch B., Luschin-Ebengreuth G., et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820-828.
56. Shapiro C.L., Halabi S., Hars V., et al. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 2011, 47:683-689.
57. Fuleihan G.E.-H., Salamoun M., Mourad Y.A., et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005, 90:3209-3214.
58. Vehmanen L., Saarto T., Elomaa I., Makela P., Valimaki M., Blomqvist C. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001, 37:2373-2378.
59. Delmas P.D., Balena R., Confravreux E., Hardouin C., Hardy P., Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997, 15:955-962.
60. Hines S.L., Mincey B.A., Sloan J.A., et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 2009, 27:1047-1053.
61. Israeli R.S., Rosenberg S.J., Saltzstein D.R., et al. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer 2007, 5:271-277.
62. Casey R, Love W, Mendoza C, Reymond D, Zarenda M. Zoledronic acid as adjunct to androgen deprivation therapy reduces bone loss in men with prostate cancer [poster]. Presented at: 21st Annual Congress of the European Association of Urology, April 5-8, 2006, Paris, France. [Abstract 139].
63. Ryan C.W., Huo D., Demers L.M., Beer T.M., Lacerna L.V. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol 2006, 176:972-978. [discussion 8].
64. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008-2012.
65. Bhoopalam N., Campbell S.C., Moritz T., et al. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol 2009, 182:2257-2264.
66. Taxel P., Dowsett R., Richter L., Fall P., Klepinger A., Albertsen P. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Int 2010, 106:1473-1476.
67. Izumi K., Mizokami A., Sugimoto K., et al. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy. Urology 2009, 73:1342-1346.
68. Planas J., Trilla E., Raventos C., et al. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int 2009, 104:1637-1640.
69. Greenspan S.L., Nelson J.B., Trump D.L., Resnick N.M. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007, 146:416-424.
70. Smith M.R., Egerdie B., Hernandez Toriz N., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745-755.
71. Coleman R.E., Marshall H., Cameron D., et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011, 365:1396-1405.
72. Coleman R.E., Winter M.C., Cameron D., et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102:1099-1105.
73. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
74. Gnant M, Mlineritsch B, Stoeger H, et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancer [poster]. Presented at: 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL. [Abstract 533].
75. Morgan G.J., Davies F.E., Gregory W.M., et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010, 376:1989-1999.
76. Fizazi K, Carducci MA, Smith MR, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with castration-resistant prostate cancer [oral presentation]. Presented at: 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL. [Abstract LBA4507].
77. Body J.J., Coleman R., Clezardin P., Ripamonti C., Rizzoli R., Aapro M. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007, 43:852-858.
78. Bock O., Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice. Clin Interv Aging 2008, 3:279-297.
79. Body J.J., Bergmann P., Boonen S., et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010, 21:1657-1680.
80. Conte P., Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004, 9:28-37.
81. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
82. Boonen S., Black D.M., Colon-Emeric C.S., et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010, 58:292-299.
83. Zometa (zoledronic acid) injection [package insert]. West Sussex, United Kingdom: Novartis Europharm Limited; 2006.
84. Santini D., Fratto M.E., Galluzzo S., Vincenzi B., Tonini G. Are bisphosphonates the suitable anticancer drugs for the elderly?. Crit Rev Oncol Hematol 2009, 69:83-94.
85. Bock O., Boerst H., Thomasius F.E., et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 2007, 7:144-148.
86. Maxwell C., Swift R., Goode M., Doane L., Rogers M. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. Clin J Oncol Nurs 2003, 7:403-408.
87. Olson K., Van Poznak C. Significance and impact of bisphosphonate-induced acute phase responses. J Oncol Pharm Pract 2007, 13:223-229.
88. Thompson K., Gordon S.A., Rogers M.J. N-bisphosphonates stimulate production of gamma/delta-T cells in human PBMC cultures by inhibiting the mevalonate pathway: clarification of the acute phase response [abstract]. J Bone Miner Res 2002, 17:S199.
89. Hewitt R.E., Lissina A., Green A.E., Slay E.S., Price D.A., Sewell A.K. The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins. Clin Exp Immunol 2005, 139:101-111.
90. Green A.E., Lissina A., Hutchinson S.L., et al. Recognition of nonpeptide antigens by human V gamma 9V delta 2 T cells requires contact with cells of human origin. Clin Exp Immunol 2004, 136:472-482.
91. Sanders J.M., Ghosh S., Chan J.M., et al. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem 2004, 47:375-384.
92. Thompson K., Roelofs A.J., Jauhiainen M., Monkkonen H., Monkkonen J., Rogers M.J. Activation of gammadelta Tcells by bisphosphonates. Adv Exp Med Biol 2010, 658:11-20.
93. Gulley J.L., Wu S., Arlen P.M., Dahut W.L. Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. Clin Genitourin Cancer 2007, 5:403-405.
94. Breen T.L., Shane E. Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency. J Clin Oncol 2004, 22:1531-1532.
95. Navarro M., Lopez R., Alana M., et al. Tonic-clonic seizure as the presentation symptom of severe hypocalcemia secondary to zoledronic acid administration. J Palliat Med 2007, 10:1226-1227.
96. Mishra A. Symptomatic hypocalcemia following intravenous administration of zoledronic acid in a breast cancer patient. J Postgrad Med 2008, 54:237.
97. Skugor M. Hypocalcemia in disease management project. Cleveland, OH: The Cleveland Clinic Foundation. http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/endocrinology/hypocalcemia/.
98. Stopeck A, Martin M, Ritchie D, et al. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: results from the extended blinded treatment phase. Presented at: San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, TX. [Poster P6-14-01].
99. Brown J.P., Prince R.L., Deal C., et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009, 1-34.
100. Aapro M., Launay-Vacher V. Importance of monitoring renal function in patients with cancer. Cancer Treat Rev 2012, 38:235-240.
101. Cardwell C.R., Abnet C.C., Cantwell M.M., Murray L.J. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010, 304:657-663.
102. Green J., Czanner G., Reeves G., Watson J., Wise L., Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010, 341:c4444.
103. Rennert G., Pinchev M., Rennert H.S. Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol 2010, 28:3577-3581.
104. Rennert G., Pinchev M., Rennert H.S., Gruber S.B. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 2011, 29:1146-1150.
105. Hatoum HT, Lin S, Smith MR, Lipton A. Persistency on monthly zoledronic acid impacts risk and frequency of skeletal complications and follow-up duration in breast cancer patients [poster]. Presented at: 46th Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2009, Chicago, IL. [Abstract 9593].
106. Hoer A., Seidlitz C., Gothe H., et al. Influence on persistence and adherence with oral bisphosphonates on fracture rates in osteoporosis. Patient Prefer Adherence 2009, 3:25-30.
107. Mangiapane S., Hoer A., Gothe H., Barghout V., Haeussler B. Higher persistency with i.v. bisphosphonates in patients with bone metastasis [abstract]. J Clin Oncol 2006, 24:698s. [Abstract 18623].
108. Lipton A. The safety of zoledronic acid. Expert Opin Drug Saf 2007, 6:305-313.
109. Bondronat® Summary of product characteristics. Roche Diagnostics GmbH and Roche Products Limited. 2010. http://www.roche-pharma.ch/gear/contents/servlet/staticfilesServlet?type=data&communityId=re714004&id=static/attachedfile/re7300002/re71700003/re72400005/AttachedFileImported_1115918026556.pdf.
110. Jackson G.H. Renal safety of ibandronate. Oncologist 2005, 10:14-18.
111. Diel I.J., Bergner R., Grotz K.A. Adverse effects of bisphosphonates: current issues. J Support Oncol 2007, 5:475-482.
112. Powles T., Paterson S., Kanis J.A., et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002, 20:3219-3224.
113. Actonel® (risedronate sodium) tablets [package insert]. North Norwich, NY: Norwich Pharmaceuticals, Inc.; 2010.
114. Launay-Vacher V., Izzedine H., Rey J.B., et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med Sci Monit 2004, 10:CR209-CR212.
115. McDermott R.S., Kloth D.D., Wang H., Hudes G.R., Langer C.J. Impact of zoledronic acid on renal function in patients with cancer: clinical significance and development of a predictive model. J Support Oncol 2006, 4:524-529.
116. Launay-Vacher V., Oudard S., Janus N., et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer 2007, 110:1376-1384.
117. Stevens L.A., Li S., Wang C., et al. Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2010, 55:S23-S33.
118. Launay-Vacher V., Spano J.P., Janus N., et al. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol 2009, 70:124-133.
119. Launay-Vacher V., Chatelut E., Lichtman S.M., Wildiers H., Steer C., Aapro M. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 2007, 18:1314-1321.
120. Estilo C.L., Van Poznak C.H., Wiliams T., et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008, 13:911-920.
121. Hoff A.O., Toth B.B., Altundag K., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008, 23:826-836.
122. Migliorati C.A., Siegel M.A., Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006, 7:508-514.
123. Weitzman R., Sauter N., Eriksen E.F., et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 2007, 62:148-152.
124. Badros A., Weikel D., Salama A., et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006, 24:945-952.
125. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005, 23:8580-8587.
126. Aragon-Ching J.B., Ning Y.M., Chen C.C., et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009, 27:221-226.
127. Christodoulou C., Pervena A., Klouvas G., et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009, 76:209-211.
128. Guarneri V., Miles D., Robert N., et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010, 122:181-188.
129. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate-related osteonecrosis of the jaw-2009 update. http://www.aaoms.org/docs/position_papers/bronj_update.pdf.
130. Fehm T., Felsenberg D., Krimmel M., Solomayer E., Wallwiener D., Hadjii P. Bisphosphonate-associated osteonecrosis of the jaw in breast cancer patients: recommendations for prevention and treatment. Breast 2009, 18:213-217.
131. Dimopoulos M.A., Kastritis E., Bamia C., et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009, 20:117-120.
132. Ripamonti C.I., Maniezzo M., Campa T., et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009, 20:137-145.
133. Bone H.G., Bolognese M.A., Yuen C.K., et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011, 96:972-980.
134. Wilkinson G.S., Baillargeon J., Kuo Y.F., Freeman J.L., Goodwin J.S. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol 2010, 28:4898-4905.
135. Rhee C.W., Lee J., Oh S., Choi N.K., Park B.J. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. Osteoporos Int 2012, 23:247-254.
136. U.S. Food and Drug Administration. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates. 2008, Created November 12, 2008. [accessed December 4].
137. Lipton A., Zheng M., Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003, 98:962-969.
138. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799-1809.
139. Misof B.M., Bodingbauer M., Roschger P., et al. Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation. Calcif Tissue Int 2008, 83:167-175.
140. Ryan P.J. An observational study of the side effect profile of IV zoledronate with successive treatments. Calcif Tissue Int 2008, 82:S246.
141. Hadji P., Gamerdinger D., Spieler W., et al. Rapid Onset and Sustained Efficacy (ROSE) study: results of a randomised, multicentre trial comparing the effect of zoledronic acid or alendronate on bone metabolism in postmenopausal women with low bone mass. Osteoporos Int 2012, 23:625-633.
142. Kiechl S., Schett G., Schwaiger J., et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation 2007, 116:385-391.
143. Sandberg W.J., Yndestad A., Oie E., et al. Enhanced T-cell expression of RANK ligand in acute coronary syndrome: possible role in plaque destabilization. Arterioscler Thromb Vasc Biol 2006, 26:857-863.
144. Wei T., Wang M., Gan L.Y., Li X. Relationship of sRANKL level and vascular calcification score to cardiovascular events in maintenance hemodialysis patients. Blood Purif 2009, 28:342-345.
145. Henry D, von Moos R, Vadhan-Raj S, et al. A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma [oral presentation]. Presented at: Joint ECCO 15-34th ESMO Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany. [Abstract 20LBA].
146. Baud'huin M., Lamoureux F., Duplomb L., Redini F., Heymann D. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci 2007, 64:2334-2350.
147. Anastasilakis A.D., Toulis K.A., Goulis D.G., et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 2009, 41:721-729.
148. Gralow J.R., Lipton A., Stopeck A.T. How do we define efficacy in comparing osteoclast-targeted agents in metastatic breast cancer?. J Clin Oncol 2011, 29:3591-3592.
149. Van Poznak C.H., Barlow W.E., Biermann J.S., et al. Reply to J.R. Gralow et al. J Clin Oncol 2011, 29:3592-3593.